Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting by Kim, Christina et al.
BioMed  Central
Page 1 of 6
(page number not for citation purposes)
BMC Public Health
Open Access Research article
Unstable housing and hepatitis C incidence among injection drug 
users in a Canadian setting
Christina Kim1, Thomas Kerr1,2, Kathy Li1, Ruth Zhang1, Mark W Tyndall1, 
Julio SG Montaner*1,2 and Evan Wood1,2
Address: 1British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, Canada and 2Department of Medicine, University 
of British Columbia, Vancouver, Canada
Email: Christina Kim - christinakim3@gmail.com; Thomas Kerr - uhri-tk@cfenet.ubc.ca; Kathy Li - kathyli@cfenet.ubc.ca; 
Ruth Zhang - rzhang@cfenet.ubc.ca; Mark W Tyndall - mtyndall@cfenet.ubc.ca; Julio SG Montaner* - jmontaner@cfenet.ubc.ca; 
Evan Wood - uhri-ew@cfenet.ubc.ca
* Corresponding author    
Abstract
Background: There has emerged growing recognition of the link between housing and health.
Since Vancouver, Canada has had increasing concerns with homelessness brought about by urban
renewal in the lead-up to the 2010 Winter Olympic Games, we evaluated hepatitis C virus (HCV)
incidence among injection drug users (IDU) with and without stable housing.
Methods: Data were derived from a collaboration between two prospective cohort studies of
IDU in Vancouver, Canada. Using Cox Proportional Hazards regression, we compared HCV
incidence among participants with and without stable housing, and determined independent
predictors of HCV incidence.
Results: Overall, 3074 individuals were recruited between May 1996 and July 2007, among whom
2541 (82.7%) were baseline HCV-infected. Among the 533 (17.3%) individuals who were not HCV-
infected at baseline, 147 tested HCV antibody-positive during follow-up, for an incidence density
of 16.89 (95% confidence interval: 14.76 – 19.32) per 100 person-years. In a multivariate Cox
regression model, unstable housing remained independently associated with HCV infection
(relative hazard = 1.47 (1.02 – 2.13).
Conclusion: HCV prevalence and incidence are high in this setting and were associated with
unstable housing. Efforts to protect existing low-income housing and improve access to housing
may help to reduce HCV incidence.
Background
The World Health Organization estimates that approxi-
mately 170 million people, or 3% of the world's popula-
tion, are infected with the hepatitis C virus (HCV). There
are presently an estimated 3 to 4 million new infections
per year [1], with illicit injection drug use being the major
risk factor for HCV. In North America and Europe, the
majority of HCV infections are associated with injection
drug use [1]. In some Western European countries, more
than 90% of injection drug users (IDU) have been found
to be HCV-positive, whereas in China prevalence ranges
from 34% to 93%, and similar prevalence has been
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reported among North American communities of IDU,
with a range of 30% to 90% [2-4].
Among IDU, there are several known associations with
new HCV infection, including older age, new onset of
injection drug use, sharing of syringes, engaging in risky
sexual behavior or prostitution, and frequent injection of
cocaine [2,4]. Although interventions such as sterile
syringe exchange programs have been shown to decrease
new HIV infection, the results have been inconsistent
when it comes to prevention of HCV infection in IDU [4-
7]. There are several explanations for why these interven-
tions have not been consistently successful in reducing
new HCV infections. HCV is thought to be transmissible
not only through syringes, but also through other drug
paraphernalia such as "cookers" and filters [8]. Risk of
hepatitis C infection is also closely linked to social and
environmental factors. One study focusing on IDU per-
ceptions of HCV risk found perceptions among IDU that
HCV is ubiquitous, less serious than HIV infection, and
associated with a lack of hygiene [9]. Environmental fac-
tors such as homelessness, fear of policing and arrest, and
oppressive relationships were also perceived to increase
HCV risk, as unstable environments disrupt individual
capacity to make risk-reducing decisions [9].
Although a lack of stable housing has been linked with
IDU taking part in high-risk, erratic, and unhygienic
injecting practices [10], the relationship between unstable
housing and HCV incidence has not been fully explored.
A previous study looked at factors associated with HCV
seroconversion amongst Vancouver IDU [11], however,
unstable housing has not been previously described as a
risk factor among long term cohorts of IDU. This is an
important question in our setting (Vancouver, Canada)
because there has been a loss of low-income housing and
an increase in homelessness as a result of urban renewal
in anticipation of the 2010 Winter Olympic Games [12].
Therefore, we sought to examine rates of HCV infection
and the possible link to unstable housing among injec-
tion drug users in this Canadian setting.
Methods
For the present study, we pooled data from participants
being followed in two well characterized cohorts of IDU
in Vancouver, Canada. The Vancouver Injection Drug
Users Study (VIDUS) is an ongoing open prospective
cohort study that was based on snowball sampling meth-
ods and outreach efforts at local services for IDU, prima-
rily the city's needle exchange program [13]. The Scientific
Evaluation of Supervised Injecting (SEOSI) cohort is an
ongoing open prospective cohort study that was based on
random sampling methods from the city's supervised
injecting facility [14]. Both cohorts have been described in
detail previously [15,16], and as previously outlined [14],
the follow-up procedures and questionnaire items used
for this analysis were identical in both studies to allow for
the merging of data sets. In brief, the studies are observa-
tional in nature and, aside from pre- and post-HIV test
counseling, no intervention is involved. Rather, both
studies involve individuals providing a venous blood
sample and responding to an interviewer-administered
questionnaire at baseline and on a semi-annual basis, and
services such as methadone and needle exchange are inde-
pendent of the study. The cohorts receive annual ethical
approval from the University of British Columbia/Provi-
dence Healthcare Research Ethics Board and are con-
ducted in a fashion consistent with other prospective
cohort studies of IDU. Participants were eligible for the
present study if they were recruited between May 1996
and July 2007.
In this study we compared HCV prevalence levels at the
time of recruitment and subsequent HCV incidence rates
among participants with and without stable housing. As
previously [17,18], stable housing was defined as living in
an apartment or house at the time of interview, and unsta-
ble housing was defined as living in a single room occu-
pancy hotel, shelter, recovery or transition house, jail, on
the street, or having no fixed address. Housing status was
a time-updated variable that was reassessed at each semi-
annual follow-up visit.
All individuals recruited during the study period were eli-
gible for the analysis of baseline HCV prevalence, whereas
individuals who were baseline HCV-negative and who
had at least one follow-up visit (to re-test for HCV infec-
tion) were eligible for the analysis of HCV incidence. To
avoid duplication, any individual who was recruited into
both cohorts was retained only in the cohort into which
they were first enrolled.
The statistical analyses of HCV incidence were undertaken
using an a priori defined statistical protocol, as follows.
First, baseline characteristics of study participants strati-
fied by housing (stable vs. unstable) were examined to
evaluate potential baseline differences between these pop-
ulations. Variables considered included: gender; age; eth-
nicity (Aboriginal vs. non-Aboriginal); residency in
Vancouver's HIV epicenter known as the Downtown East-
side (DTES); use of methadone; sex trade involvement;
daily heroin injection; daily cocaine injection; daily meth-
amphetamine injection; daily crack smoking; used syringe
borrowing; unsafe sex (defined as vaginal or anal sex with-
out a condom); incarceration (defined as being in deten-
tion, jail, or prison). All variable definitions were identical
to earlier studies and most heroin in Vancouver is
believed to be from Asia, primarily Burma [13,19]. All
behavioral variables were in reference to the prior six
months, except for methadone use, which referred to cur-BMC Public Health 2009, 9:270 http://www.biomedcentral.com/1471-2458/9/270
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rent use. Pearson's chi-squared test was used to compare
categorical variables, and continuous variables were com-
pared using the Wilcoxon rank sum test.
We calculated the incidence density of HCV infection
among participants with and without stable housing. As
previously [20], the date of HCV seroconversion was esti-
mated using the midpoint between the last negative and
the first positive antibody test results. Participants remain-
ing persistently HCV seronegative were censored at the
time of their most recent available HCV antibody test
result prior to December 2005.
We also calculated the unadjusted and adjusted relative
hazards of HCV seroconversion using Cox proportional
hazards regression. Here, all behavioral variables were
treated as time-updated covariates based on semi-annual
follow-up data. For the multivariate model, a fixed model
was built that adjusted for all variables described above
that were statistically associated with HCV seroconversion
in unadjusted analyses. Analyses were conducted using
SAS 9.1 (Cary, NC); the threshold for statistical signifi-
cance was set at p < 0.05. All p-values were two-sided.
Results
During the study period, 3074 unique individuals were
recruited into either VIDUS or SEOSI, among whom 1973
(64.2%) reported living in unstable housing at baseline.
Of the 3074 recruited individuals, 980 (31.9%) were
female and 730 (23.8%) identified themselves as Aborig-
inal. Overall, the baseline HCV prevalence was 82.7%. In
VIDUS, the baseline HCV prevalence was higher among
those with unstable housing at baseline (84.0% vs.
78.8%, p = 0.004); however, in SEOSI, baseline HCV prev-
alence was no different among those with unstable hous-
ing at baseline (86.6% vs. 83.2%, p = 0.119; combined
cohort: 84.3% vs. 79.7%, p = 0.001). At baseline, 533 par-
ticipants were HCV-negative, and 390 (73.2%) of these
had at least one follow-up visit and were therefore
included in the analysis of HCV incidence. Among the
1101 individuals not in unstable housing at baseline, 693
(62.9%) subsequently reported being in unstable housing
at least once during follow-up, whereas among the 1973
individuals in unstable housing at baseline, 1217 (61.7%)
subsequently reported being in stable housing at least
once.
Table 1 shows the demographic and risk behavior profile
of baseline HCV-negative participants stratified by stable
versus unstable housing. As shown here, participants with
unstable housing were more likely to be Aboriginal (p =
0.030), to reside in the Downtown Eastside (p < 0.001), to
be sex-trade involved (p = 0.014), and to inject metham-
phetamine daily (p = 0.014). Participants with unstable
housing were less likely to report use of methadone (p =
0.014), to report syringe sharing (p = 0.027) and to use
heroin daily (p = 0.013). There were no significant differ-
ences based on gender, incarceration within the last 6
months, daily cocaine use, daily crack smoking, and
unsafe sexual practices.
Among the 533 (17.3%) individuals who were not HCV-
infected at baseline, 147 tested HCV antibody-positive
during follow-up, for an incidence density of 16.89 (95%
confidence interval [CI]: 14.76 – 19.32) per 100 person-
years. Table 2 shows the results of the unadjusted and
adjusted Cox proportional hazard regression analyses of
the time to HCV infection for HCV risk behaviors and
demographic characteristics. As shown here, in unad-
justed Cox regression analyses, the relative hazard [RH] of
HCV seroconversion for those with unstable versus stable
housing was 1.71 (95% CI: 1.22 – 2.39; p = 0.002). After
adjusting for all variables associated with the time to HCV
infection in univariate analyses, as well as for cohort of
initial recruitment, the RH of HCV infection was 1.47
(95% CI: 1.02 – 2.13; p = 0.041) for participants with
unstable versus stable housing. Other variables associated
with HCV seroconversion in the adjusted Cox regression
analyses included syringe sharing, with a RH of 1.57 (95%
CI: 1.08 = 2.29; p = 0.020); daily heroin injection with a
RH of 1.61 (95% CI: 1.13 – 2.28; p = 0.008); and daily
cocaine injection with a RH of 1.48 (95% CI; 1.00 – 2.19;
p = 0.049).
Discussion
The present study demonstrated a high prevalence and
incidence of HCV among IDU in a Canadian setting.
Among those individuals who were not HCV-infected at
baseline, the incidence of new HCV infection was consid-
erably high. Of the participants in the VIDUS and SEOSI
cohorts, 67.9% lacked stable housing at baseline, and
HCV incidence was associated with residing in unstable
housing in the six months prior to testing HCV positive.
A key finding of the present study is the independent asso-
ciation between residing in unstable housing environ-
ments and acquiring hepatitis C. Previous studies have
clearly demonstrated that unstable housing among IDU is
associated with hazardous and unhygienic injecting prac-
tices, such as using drugs in public places, pooling money
to buy drugs, and sharing drug-injecting equipment (e.g.,
needles, spoons) [10], which leads to an increased risk of
blood-borne infections [21]. It is likely that the associa-
tion between unstable housing and HCV incidence is
explained by the fact that individuals in unstable housing
spend greater time in environments where risk behavior is
elevated as a result of the above mechanisms. Past
research has also shown that unstable housing is not only
associated with poor health outcomes, but also with
increased emergency department and hospital service useBMC Public Health 2009, 9:270 http://www.biomedcentral.com/1471-2458/9/270
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[22], and as a result the medical costs of homeless individ-
uals in British Columbia are 33% higher per year than
those of housed persons [23]. The disorganized lifestyle
associated with unstable housing may also act as a barrier
for IDU who wish to access primary care and addiction
treatment programs. Our study supports this hypothesis,
as those with unstable housing were less likely to be
involved in a methadone treatment program. As a result,
strategies to protect housing for IDU as well as to increase
housing for this population, along with interventions that
reduce HCV risk behavior among unstable housed indi-
viduals, will likely help reduce HCV incidence.
The link between high incidence of HCV and unstable
housing is particularly concerning here in Vancouver,
Canada, where the number of homeless persons rose by
106% from 2002 to 2005. The number of homeless per-
sons living on the streets of Vancouver's DTES is predicted
to exceed 3000 by the time of the 2010 Olympics [23].
Urban renewal in preparation for the 2010 Olympics has
led to increased property speculation and increasing prop-
erty values in the DTES, thereby reducing available low-
income housing. The high incidence of HCV infection
among local IDU, as well as the risk of HCV infection
associated with unstable housing, are indications of the
pressing need for both affordable housing and addiction
treatment programs. Affordable, stable living environ-
ments can decrease hazardous IDU practices that add to
the risk of acquiring HCV and, paired with increased
access to addiction treatment programs, may decrease the
Table 1: Baseline demographic characteristics of HCV-negative IDU stratified by unstable housing
Characteristic Stable Housing n = 175 (%) Unstable Housing n = 215 (%) Odds Ratio (95% CI) p-value
Gender
Male 122 (69.71) 152 (70.70)
Female 53 (30.29) 63 (29.30) 0.95 (0.62 – 1.48) 0.833
Age
Median (IQR) 28 (22 – 35) 28 (23 – 40) 1.01 (0.99 – 1.03) 0.268
Aboriginal ethnicity
No 153 (87.43) 170 (79.07)
Yes 22 (12.57) 45 (20.93) 1.84 (1.06 – 3.21) 0.030
DTES residence*
No 113 (64.57) 61 (28.37)
Yes 62 (35.43) 154 (71.63) 4.60 (3.00 – 7.06) <0.001
On methadone†
No 154 (88.00) 204 (94.88)
Yes 21 (12.00) 11 (5.12) 0.40 (0.19 – 0.84) 0.014
Incarceration
No 92 (77.97) 123 (71.51)
Yes 26 (22.03) 49 (28.49) 1.41 (0.82 – 2.44) 0.218
Sex trade involved*
No 146 (83.43) 157 (73.02)
Yes 29 (16.57) 58 (26.98) 1.86 (1.13 – 3.06) 0.014
Syringe sharing*
No 105 (60.00) 152 (70.70)
Yes 70 (40.00) 63 (29.30) 0.62 (0.41 – 0.95) 0.027
Heroin use*
Less than daily 94 (53.71) 142 (66.05)
Daily use 81 (46.29) 73 (33.95) 0.60 (0.40 – 0.90) 0.013
Cocaine use*
Less than daily 146 (83.43) 167 (77.67)
Daily use 29 (16.57) 48 (22.33) 1.45 (0.87 – 2.41) 0.156
Crack smoking
Less than daily 147 (84.00) 168 (78.14)
Daily use 28 (16.00) 47 (21.86) 1.47 (0.88 – 2.46) 0.144
Methamphetamine injection
Less than daily 156 (89.14) 172 (80.00)
Daily 19 (10.86) 43 (20.00) 2.05 (1.15 – 3.67) 0.014
Unsafe sex**
No 100 (57.14) 133 (61.86)
Yes 75 (42.86) 82 (38.14) 0.82 (0.55 – 1.23) 0.345
Note: IDU = injection drug user; DTES = Downtown Eastside. *Indicates behavior during the six-month period prior to the baseline interview. 
†Indicates current use. **Unsafe sex was defined as vaginal or anal sex without a condom.BMC Public Health 2009, 9:270 http://www.biomedcentral.com/1471-2458/9/270
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alarming incidence of blood-borne infections such as
HCV.
The present study has several limitations. Both VIDUS and
SEOSI were created to evaluate risk factors for HIV and
HCV transmission but were not developed with the spe-
cific aim of evaluating the role of housing. As well, the
study design did not allow for determination of the tem-
poral relationship between HCV infection and unstable
housing, and although an independent relationship
between unstable housing and HCV infection was found,
a causal relationship cannot be stated. Specifically, it is
possible that risky drug injection behaviour resulted in
subjects losing stable housing and that this was associated
with, but did not cause new HCV infection. In addition, as
a result of limited events and statistical power, we used a
combined definition of unstable housing, and future
studies should seek to examine the impact of specific
unstable housing environments on HCV risk. Qualitative
research may also be helpful in better describing how
unstable housing environments contribute to HCV risk.
There was also a loss of baseline HCV-negative patients to
follow-up, which may have influenced results. As well,
previous studies of IDU have suggested that socially desir-
able responding may lead to under-estimation of certain
HIV risk behaviors [24], and this likely also pertains to
HCV risk factor reporting. However, other studies have
suggested self-reports to be valid [25]. While this may
have influenced our risk factor analyses, it does not
explain the observed differences in both HCV prevalence
and incidence. Similarly, studies of marginalized popula-
tions may be subject to concerns related to generalizabil-
ity, as it is not possible to derive a random sample of the
overall population. This concern is relevant to all prospec-
tive cohort studies of IDU, and it is noteworthy that the
demographics of both VIDUS and SEOSI are consistent
with what is known about the demographics of the popu-
lations of IDU in the local community [14]. A final limi-
tation is that differing recruitment methods were used to
derive the VIDUS and SEOSI cohorts. We sought to
address this limitation by adjusting for cohort of recruit-
ment in our multivariate model.
Conclusion
In summary, the present study demonstrates that HCV
prevalence and incidence are high among IDU in our set-
ting, and that unstable housing is a risk factor for HCV
infection. The current situation here in Vancouver
requires an urgent response, including protection of exist-
ing low-income housing and increased access to afforda-
ble housing. These responses, along with increased access
to addiction treatment, may reduce HCV incidence in this
setting.
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